Free Trial
NASDAQ:BSGM

Biosig Technologies 8/14/2023 Earnings Report

Biosig Technologies logo
$5.86 -0.45 (-7.13%)
Closing price 04:00 PM Eastern
Extended Trading
$5.96 +0.10 (+1.77%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biosig Technologies EPS Results

Actual EPS
-$1.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biosig Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biosig Technologies Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biosig Technologies' next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Biosig Technologies Earnings Headlines

BioSig Technologies, Inc. (BSGM) - Yahoo Finance
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Biosig Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biosig Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biosig Technologies and other key companies, straight to your email.

About Biosig Technologies

Biosig Technologies (NASDAQ:BSGM) is a U.S.-based medical device company that designs and commercializes advanced biomedical signal processing solutions for improving the acquisition, analysis, and interpretation of physiologic signals. Its flagship offering, the PURE EP System, provides real-time noise reduction and signal enhancement during cardiac electrophysiology procedures, enabling physicians to obtain clearer intracardiac electrical readings. This platform is built on proprietary hardware and software algorithms that isolate low-amplitude signals, helping clinicians make more precise diagnoses and treatment decisions.

Founded in 2008 and headquartered in New York, Biosig leverages deep expertise in bioelectronic signal processing to tackle challenges in cardiac catheterization laboratories. The PURE EP System has received 510(k) clearance from the U.S. Food and Drug Administration, and the company is actively pursuing CE marking and other regulatory approvals to expand into European and Asia-Pacific markets. Collaborations with leading academic medical centers and electrophysiology specialists support ongoing clinical evaluations and product refinements.

Beyond electrophysiology, Biosig is exploring broader applications of its signal processing technology in areas such as neuromonitoring and hemodynamic assessment. Its research and development efforts focus on delivering high-fidelity biometric data in real time, with the aim of improving patient outcomes, streamlining clinical workflows, and reducing procedure durations. By leveraging its patented platform, the company seeks to extend its product portfolio to address unmet needs across multiple medical disciplines.

Biosig serves hospitals, ambulatory surgical centers, and research institutions throughout North America and is working to establish a global distribution network through strategic partnerships. The company is guided by a management team with extensive experience in medical technology innovation, clinical research, and commercialization. Biosig’s leadership includes executives who have held senior roles at leading medical device and bioengineering firms, providing a strong foundation for scaling operations and advancing its technology roadmap.

View Biosig Technologies Profile

More Earnings Resources from MarketBeat